|
 Investor
Relations
CEO Message
To Our Stockholders:
The past year has been a transitional one for The Quigley Corporation, as we
continue our development into a full-service pharmaceutical and natural health
entity. We have made remarkable progress in the seven years since the
inception of Quigley Pharma, with seven patents, one approved Investigational
New Drug application (IND), one drug in phase IIb human clinical trials and
five compounds in preclinical studies.
We could not have attained these
important milestones without the flexibility, talent and planning available
within the Company and on the Board. Although bringing natural therapeutic
pharmaceutical drugs to market is a lengthy and involved process, I can assure
you it is a worthwhile investment, one that may provide patients with
medications for a variety of health concerns and ensure the continued
financial strength of our Company.
COLD-EEZE® faced several challenges in 2006, including significantly increased
competition from new entrants into the immune-booster market, an unusually
warm fall and late winter, and a late cold/flu season. However, COLD-EEZE was
still able to provide substantial support for Quigley Pharma's research and
development, confirming the decision made in 2000 to enter the ethical
pharmaceutical market.
Darius International, through its wholly-owned subsidiary Innerlight Inc.,
also experienced a drop in sales in 2006. The decline was the direct result of
fewer independent distributors and continued litigation. However, I am
encouraged by the fact that this year Darius fully implemented its global
growth strategy, opening corporate headquarters in Singapore and Taiwan and
adding 14 new countries to its international distribution.
We could not have attained these important milestones without the flexibility,
talent and planning available within the Company and on the Board.
The Quigley Corporation continues to move forward, closer to its goals -- as
Quigley Pharma creates a new direction for pharmaceutical development. I
invite you to read more about our efforts and our successes in 2006.
Thank you for your ongoing support.
Guy J. Quigley
President, Chairman & Chief Executive Officer
FORWARD-LOOKING STATEMENTS
In addition to historical information, this Webpage contains forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, management of growth, competition, pricing pressures on the Company’s product, industry growth and general economic conditions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date hereof. The Company undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements.
CERTAIN RISK FACTORS
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an Investigational New Drug (“IND”) or take any other action to allow its formulations to be studied or marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in-vitro tests do not necessarily mean the formula test compound, referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in other sections of the filing as well as in other documents the Company files from time to time with the Securities and Exchange Commission.
|
